Literature DB >> 18342202

Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.

Stefan Uckert1, Michael Sormes, George Kedia, Friedemann Scheller, Wolfram H Knapp, Udo Jonas, Christian G Stief.   

Abstract

OBJECTIVES: To further evaluate the mechanism of action of phosphodiesterase (PDE) inhibitors on the human prostate, the effects of PDE4 and PDE5 inhibitors on the tension induced by norepinephrine (NE) and on the intracellular levels of cyclic nucleotides in isolated human prostatic tissue were investigated.
METHODS: Using the organ bath technique, the effects of increasing concentrations (1 nM to 10 microM) of the PDE5 inhibitors sildenafil, tadalafil, and vardenafil and the PDE4 inhibitors rolipram and RP 73401 on the tension induced by NE (40 microM) of prostate strip preparations were investigated. The accumulation of cyclic guanosine monophosphate and cyclic adenosine monophosphate in response to drug exposure was determined by radioimmunoassays.
RESULTS: The tension induced by NE was dose dependently reversed by the drugs with the following rank order of efficacy: tadalafil greater than RP 73401 greater than rolipram greater than or equal to vardenafil greater than sildenafil. The maximal reversion of tension values ranged from 52.3% (tadalafil) to 17% (sildenafil). Of the PDE inhibitors, only tadalafil induced a 50% reversion of the initial tension. The most prominent enhancement in tissue cyclic adenosine monophosphate was registered in response to RP 73401 (11-fold), and cyclic guanosine monophosphate levels were significantly elevated by tadalafil, vardenafil, and sildenafil (28-fold, 12-fold, and 3-fold, respectively).
CONCLUSIONS: Our results have demonstrated that drugs interfering with the cyclic nucleotide-mediated pathways can reverse the tension induced by NE in isolated prostatic tissue and elevate cyclic adenosine monophosphate and cyclic guanosine monophosphate. Our findings serve to explain how PDE inhibitors can affect symptoms of lower urinary tract symptoms and benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342202     DOI: 10.1016/j.urology.2007.10.051

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

1.  An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Zhe Jin; Zhi-Chao Zhang; Ji-Hong Liu; Jun Lu; Yu-Xin Tang; Xiang-Zhou Sun; Wei-Dong Song; Bing Gao; Ying-Lu Guo; Zhong-Cheng Xin
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

Review 2.  [Etiology and pathophysiology of benign prostate hyperplasia].

Authors:  A Roosen; C Gratzke; A Herrlemann; G Magistro; F Strittmatter; P Weinhold; S Tritschler; C G Stief
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

Review 3.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

Review 4.  Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Authors:  Selim Cellek; Norman E Cameron; Mary A Cotter; Christopher H Fry; Dapo Ilo
Journal:  Nat Rev Urol       Date:  2014-03-11       Impact factor: 14.432

Review 5.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 6.  Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action.

Authors:  Osamu Yokoyama; Yasuhiko Igawa; Masayuki Takeda; Takafumi Yamaguchi; Masahiro Murakami; Lars Viktrup
Journal:  Ther Adv Urol       Date:  2015-10

Review 7.  Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2012-09       Impact factor: 3.923

8.  Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.

Authors:  Stefan Ückert; Eginhard S Waldkirch; Axel S Merseburger; Markus A Kuczyk; Matthias Oelke; Petter Hedlund
Journal:  World J Urol       Date:  2013-03-09       Impact factor: 4.226

Review 9.  The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.

Authors:  Mehmet Umul; Tekin Ahmet Serel
Journal:  Turk J Urol       Date:  2013-12

Review 10.  Phosphodiesterase-5 expression and function in the lower urinary tract: a critical review.

Authors:  Ching-Shwun Lin; Maarten Albersen; Zhongcheng Xin; Mikio Namiki; Dieter Muller; Tom F Lue
Journal:  Urology       Date:  2013-01-17       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.